Sign in

CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company

Dianthus Therapeutics, Inc. /DE/

Sign in to watch
Ticker
DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
929-999-4055
Business address
7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
Former names
Magenta Therapeutics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 3 Insider Initial Statement of Ownership
  3. 4 Other acquisition Director acquired 4,100 shares (other)
  4. 4 Open-market sale Chief People Officer sold 5,736 shares at $6.73 ($38,603)
  5. 4 Open-market sale See Remarks sold 5,736 shares at $6.73 ($38,603)
  6. 4 Open-market sale Chief Commercial Officer sold 6,238 shares at $6.73 ($41,982)
  7. 4 Open-market sale See Remarks sold 14,340 shares at $6.73 ($96,508)
  8. 4 Open-market sale See Remarks sold 6,103 shares at $6.73 ($41,073)
  9. 4 Open-market sale See Remarks sold 5,736 shares at $6.73 ($38,603)
  10. 4 Open-market sale Chief Technical Officer sold 5,694 shares at $6.73 ($38,321)
  11. 4 Grant or award See Remarks acquired 20,000 shares (grant or award)
  12. 4 Grant or award Chief People Officer acquired 20,000 shares (grant or award)
  13. 4 Grant or award Chief Commercial Officer acquired 20,000 shares (grant or award)
  14. 4 Grant or award See Remarks acquired 20,000 shares (grant or award)
  15. 4 Grant or award See Remarks acquired 50,000 shares (grant or award)
  16. 4 Grant or award Chief Technical Officer acquired 20,000 shares (grant or award)
  17. 4 Grant or award See Remarks acquired 20,000 shares (grant or award)
  18. 4 Other disposition 10% owner disposed of 1,250,000 shares (other)
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 8 of 15 · 290 filings